10X Must Face Bio-Rad, Harvard’s Massachusetts Patent Claims

May 1, 2020, 8:23 PM

10X Genomics can’t escape gene-research patent infringement claims brought by rival Bio-Rad Laboratories Inc. and Harvard University, a Boston federal court said.

Bio-Rad sufficiently alleged that 10X infringed three patents indirectly and willfully, and induced others to infringe, in support of claims that 10X had sought to dismiss, the court said Thursday.

Bio-Rad accused 10X’s “Next GEM” platform of infringing three patents covering its “Droplet Digital” technology, used to split biological samples into microdroplets and allow researchers to create large numbers of samples with a small overall volume and a minimum amount of handling. 10X licensed two of the patents ...

To read the full article log in. To learn more about a subscription click here.